“PhRMA Act” introduced in House
Executive Summary
Pharmaceutical company CEOs would be required to annually attest that all evidence of serious adverse events for a drug has been disclosed to HHS under the Pharmaceutical Research & Manufacturers Accountability Act. Introduced by Reps. Pete Stark (D-Calif.) and Marion Berry (D-Ark.) on Feb. 16, the "PhRMA Act" (HR 870) would authorize jail time and fines for CEOs and other executives for "knowing concealment...of evidence of a serious adverse drug experience." The bill also would authorize imposition of fines if post-marketing studies are not completed in a specified time period...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.